Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
-
Patent number: 11053305Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.Type: GrantFiled: January 24, 2020Date of Patent: July 6, 2021Assignee: Q32 Bio Inc.Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
-
Patent number: 11053316Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: GrantFiled: October 16, 2018Date of Patent: July 6, 2021Assignee: Xencor, Inc.Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
-
Patent number: 11033590Abstract: The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.Type: GrantFiled: June 29, 2020Date of Patent: June 15, 2021Assignee: ORTHOBIO THERAPEUTICS, INC.Inventors: Peter J. Millett, Iain Alasdair Russell, Matthew J. Allen
-
Patent number: 11007250Abstract: The present disclosure provides methods and kits for treating pain. More particularly, the present disclosure relates to methods of using PD-L1/PD-1-associated compounds to treat pain and/or bone destruction from bone cancer, and associated kits. The present disclosure also provides methods to assess the efficacy of compounds to suppress PD-1-associated nociceptive neuron activity.Type: GrantFiled: May 12, 2018Date of Patent: May 18, 2021Assignee: Duke UniversityInventors: Ru-Rong Ji, Gang Chen, Zilong Wang, Changyu Jiang, Kaiyuan Wang
-
Patent number: 11001628Abstract: The present application n relates to a pharmaceutical composition comprising a PD-1 antibody and an M-CSF antibody. The combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer.Type: GrantFiled: July 27, 2016Date of Patent: May 11, 2021Assignee: NOVARTIS AGInventors: Marie-Louise Fjaellskog, John Scott Cameron, Zhu Cao, Daniela Cipolletta, Kenzie MacIsaac
-
Patent number: 11001635Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.Type: GrantFiled: June 28, 2019Date of Patent: May 11, 2021Assignee: Gensun Biopharma Inc.Inventors: Jackie Sheng, Bo Liu, Margaret Karow
-
Patent number: 10973914Abstract: A polypeptide is disclosed that binds tumor-associated antigens (TAA) on the surface of cancer cells and a NKG2D receptor. The NKG2D receptor is expressed on the surfaces of killer cells such as natural killer cells, T cells, natural killer T cells, and gamma delta T cells. In some cases, the TAA is CS-1 or EGFRvIII. Also disclosed are polynucleotides encoding the disclosed polypeptides, vectors comprising the disclosed polynucleotides, and host cells comprising the disclosed vectors. Also disclosed are bivalent antibodies comprising the disclosed polypeptides. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies. Also disclosed are methods of treating cancer in a subject using the disclosed bi-specific antibodies.Type: GrantFiled: February 22, 2016Date of Patent: April 13, 2021Assignee: OHIO STATE INNOVATION FOUNDATIONInventors: Jianhua Yu, Michael Caligiuri, Wing Keung Chan
-
Patent number: 10968276Abstract: The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: GrantFiled: March 7, 2014Date of Patent: April 6, 2021Assignee: Xencor, Inc.Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
-
Patent number: 10941190Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.Type: GrantFiled: November 4, 2016Date of Patent: March 9, 2021Assignee: Genentech, Inc.Inventors: Justin Scheer, Whitney Shatz, Domingos Ng
-
Patent number: 10906955Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.Type: GrantFiled: June 1, 2018Date of Patent: February 2, 2021Assignees: Pfizer Inc., Boston Medical Center CorporationInventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
-
Patent number: 10899799Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n ore as defined in claim 1.Type: GrantFiled: February 28, 2017Date of Patent: January 26, 2021Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Sylvie Bay, Claude Leclerc, Richard Lo-Man
-
Patent number: 10894830Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.Type: GrantFiled: November 1, 2016Date of Patent: January 19, 2021Assignee: Janssen Biotech, Inc.Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A DeAngelis, Sandra Santulli-Marotto, Karla R Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
-
Patent number: 10870702Abstract: Provided herein is a method for determining cancer treatment using an immune modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject is dysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune modulating therapy is administered to treat cancer in the subject. Alternatively, when the lymphatic system is dysregulated, an immune modulating therapy is selected to treat cancer in the subject, which immune modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.Type: GrantFiled: October 9, 2018Date of Patent: December 22, 2020Assignee: ENSEMLBLE GROUP HOLDINGSInventors: Michael David Kuo, Ching-Yu Huang
-
Patent number: 10870701Abstract: The present invention provides multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. The present invention further provides uses of the MSFPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSFPs. Also provided are anti-EpCAM antibodies or antigen-binding fragments thereof.Type: GrantFiled: March 15, 2017Date of Patent: December 22, 2020Assignee: Generon (Shanghai) Corporation Ltd.Inventors: Yumin Cui, Zhihua Huang, Hanyang Chen, Xinfeng Zhang, Bo Qi, Xiaoqiang Yan
-
Patent number: 10864180Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.Type: GrantFiled: April 22, 2016Date of Patent: December 15, 2020Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim
-
Patent number: 10822428Abstract: An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein the Fab region comprises a first covalent link between a first heavy chain and a first light chain of the Fab region and a second covalent link between a second heavy chain and a second light chain of said Fab region, wherein a position of the first covalent link relative to the first heavy chain is different to a position of the second covalent link relative to the second heavy chain. Methods of generating same and uses thereof are also provided.Type: GrantFiled: March 2, 2017Date of Patent: November 3, 2020Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Itai Benhar, Lilach Vaks
-
Patent number: 10815308Abstract: Bispecific antigen binding molecules (e.g., antibodies) that bind blood clotting factors, factor IXa (FIXa) and factor X (FX), and enhance the FIXa-catalysed activation of FX to FXa. Use of the bispecific antigen binding molecules to control bleeding, by replacing natural cofactor FVIIIa which is deficient in patients with haemophilia A.Type: GrantFiled: December 20, 2019Date of Patent: October 27, 2020Assignee: KYMAB LIMITEDInventors: Wei Wang, E-Chiang Lee, John Kenneth Blackwood, Roberto Magliozzi
-
Patent number: 10787500Abstract: Methods for purifying multispecific antibodies on interest (MAIs) that co-engage at least two different antigens or epitopes (also referred to targets, used interchangeably throughout), from compositions comprising the MAI and parental homodimeric antibody species are provided, as well as reagents which may be used to practice such methods.Type: GrantFiled: April 8, 2016Date of Patent: September 29, 2020Assignee: Adimab, LLCInventors: Juergen Hermann Nett, K. Dane Wittrup, Maximiliano Vasquez
-
Patent number: 10766958Abstract: Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.Type: GrantFiled: September 18, 2017Date of Patent: September 8, 2020Assignee: Celgene CorporationInventor: Garth E. Ringheim
-
Patent number: 10766967Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 30, 2016Date of Patent: September 8, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Patent number: 10759870Abstract: Bispecific antibodies whose FIX activation-inhibiting activity is not elevated and whose FVIII cofactor function-substituting activity is elevated have been successfully discovered.Type: GrantFiled: September 27, 2018Date of Patent: September 1, 2020Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yuri Teranishi, Kazuki Kato, Hikaru Koga, Tomoyuki Igawa, Kazuki Yamaguchi, Tetsuhiro Soeda
-
Patent number: 10751414Abstract: Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.Type: GrantFiled: September 18, 2017Date of Patent: August 25, 2020Assignee: Celgene CorporationInventors: Henry H. Chan, Eun Mi Hur, Roli Khattri, Monica Leung, Garth E. Ringheim, Peter H. Schafer
-
Patent number: 10738127Abstract: The present invention provides antibodies that target an E-cadherin linker segment, homologous to other segments adjacent to cell membrane in cancer cell shed proteins for diagnosis and therapy of cancers of epithelial origin. We design this peptide based in experimental observations that demonstrate shedding of E-cadherin and extracellular domains of other cell surface proteins during cancer progression and metastasis and based on our observation that a proline residue after transmembrane domain is present in many proteins on the cell surface that are targets for proteolytic processing. The corresponding antibodies were validated in vitro and in vivo using animal models and have showed no toxicity and significant tumor regression for gastric cancer, including potentiation of commercial drug, when utilized in combination.Type: GrantFiled: June 12, 2017Date of Patent: August 11, 2020Assignee: Veritas Biotecnologia LTDAInventors: Sandra Rodrigues Pereira Faça, Vitor Marcel Faça
-
Patent number: 10688119Abstract: The present disclosure relates to inhibitors of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) for the treatment of lipoprotein metabolism disorders.Type: GrantFiled: March 18, 2016Date of Patent: June 23, 2020Assignee: Aarhus UniversitetInventors: Camilla Gustafsen, Peder Sondergaard Madsen, Simon Glerup Pedersen
-
Patent number: 10683351Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human DLL3 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising the polynucleotide and a host cell transformed or transfected with the polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of the antibody construct and a kit comprising the antibody construct.Type: GrantFiled: March 4, 2019Date of Patent: June 16, 2020Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Tobias Raum, Claudia Blümel, Christoph Dahlhoff, Patrick Hoffmann, Peter Kufer, Ralf Lutterbüse, Elisabeth Nahrwold, Jochen Pendzialek
-
Patent number: 10683353Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.Type: GrantFiled: July 11, 2014Date of Patent: June 16, 2020Assignee: THE SCRIPPS RESEARCH INSTITUTEInventors: Feng Wang, Yong Zhang, Yan Liu, Peter G. Schultz
-
Patent number: 10669350Abstract: The invention relates to single domain VHH fragments which specifically bind to and inhibit superoxide dismutase and/or bind to and inhibit catalase and/or bind to and inhibit superoxide dismutase and catalase, in particular for the use in the therapy of tumor diseases.Type: GrantFiled: February 1, 2016Date of Patent: June 2, 2020Inventors: Georg Bauer, Manfred Motz
-
Patent number: 10640572Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.Type: GrantFiled: March 29, 2017Date of Patent: May 5, 2020Assignee: Genentech, Inc.Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
-
Patent number: 10633451Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.Type: GrantFiled: January 24, 2013Date of Patent: April 28, 2020Assignees: Hoffmann-La Roche Inc., Ludwig-Maximillians-Universität MünchenInventors: Carole Bourquin, Raffaella Castoldi, Stefan Endres, Christian Klein, Sebastian Kobold, Gerhard Niederfellner, Claudio Sustmann
-
Patent number: 10633457Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.Type: GrantFiled: June 2, 2017Date of Patent: April 28, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Wolfgang Schaefer, Klaus Mayer
-
Patent number: 10626190Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: October 27, 2017Date of Patent: April 21, 2020Assignee: Amphivena Therapeutics, Inc.Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Patent number: 10611832Abstract: Disclosed are methods for the reduction, prevention or treatment of cardiovascular events and/or cardiovascular diseases, including acute cardiovascular disease or chronic cardiovascular disease using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies and fragments thereof). The present disclosure also relates to methods for prevention or treatment of cardiovascular events and/or cardiovascular diseases, including by reducing a cardiovascular event or disease.Type: GrantFiled: July 11, 2017Date of Patent: April 7, 2020Assignee: XOMA (US) LLCInventors: Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein
-
Patent number: 10556964Abstract: Provided are compositions comprising a MSBODY and a cytotoxic immune cell (e.g., Cytokine-induced killer cell) to form Armed Activated CIK cells (ACCs), wherein the MSBODY comprising a first antigen binding moiety that has specificity for a tumor antigen, and a second antigen binding moiety that binds to the cell. Provided are also methods preparing a composition comprising a MSBODY and a cytotoxic immune cell, and methods for treating patients with CIK cells armed with bispecific antibodies.Type: GrantFiled: July 21, 2014Date of Patent: February 11, 2020Assignee: Wuhan YZY Biopharma Co., Ltd.Inventors: Pengfei Zhou, Tao Wang, Liu Hu, Mi Huang, Lijuan Fang, Yang Liu
-
Patent number: 10543261Abstract: The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.Type: GrantFiled: August 28, 2013Date of Patent: January 28, 2020Assignees: Osaka University, AnGes, Inc.Inventors: Hironori Nakagami, Mariko Kyutoku, Ryuichi Morishita, Hideki Tomioka
-
Patent number: 10538585Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.Type: GrantFiled: May 10, 2017Date of Patent: January 21, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
-
Patent number: 10487150Abstract: SIRPabodies comprise an immunoglobulin variable region, which may specifically bind a tumor antigen, viral antigen, etc., fused to a sequence comprising a binding domain of SIRP?. The binding domain of SIRP? comprises at least the N-terminal Ig-like domain of SIRP?, and may further comprise additional SIRP? sequences. The SIRPabodies find use in therapeutic methods that benefit from the combined activity of blocking CD47 activity, and antibody targeting, e.g. in the treatment of cancer, etc. In some specific embodiments, the SIRPabody comprises anti-CD20 activity and a SIRP? binding domain; anti-CD99 and a SIRP? binding domain; or anti-TIM3 activity and a SIRP? binding domain.Type: GrantFiled: August 23, 2018Date of Patent: November 26, 2019Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ravindra Majeti, Emily Piccione Griffin
-
Patent number: 10479831Abstract: This invention relates to chimeric and humanized antibodies that specifically bind the BCR complex, and particularly chimeric and humanized antibodies to the BCR complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.Type: GrantFiled: May 31, 2017Date of Patent: November 19, 2019Assignee: MacroGenics, IncInventors: Leslie S. Johnson, Ling Huang
-
Patent number: 10472427Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.Type: GrantFiled: June 26, 2017Date of Patent: November 12, 2019Assignee: Xencor, Inc.Inventors: John Desjarlais, Gregory Moore, Rumana Rashid, Matthew Bernett
-
Patent number: 10472419Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.Type: GrantFiled: February 14, 2017Date of Patent: November 12, 2019Assignees: Novartis AG, DANA-FARBER CANCER INSTITUTE, INC., Children's Medical Center CorporationInventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
-
Patent number: 10465006Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: GrantFiled: July 4, 2014Date of Patent: November 5, 2019Assignee: GENMAB A/SInventors: Edward Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Paul Parren
-
Patent number: 10457745Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: December 20, 2016Date of Patent: October 29, 2019Assignee: Bioverativ USA Inc.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Patent number: 10457732Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: May 5, 2017Date of Patent: October 29, 2019Assignee: MEDIMMUNE, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Patent number: 10450382Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: December 20, 2016Date of Patent: October 22, 2019Assignee: Bioverativ USA Inc.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Patent number: 10421816Abstract: The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.Type: GrantFiled: May 26, 2016Date of Patent: September 24, 2019Assignee: UCB BIOPHARMA SPRLInventors: Ralph Adams, Emma Dave, David Paul Humphreys
-
Patent number: 10407501Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.Type: GrantFiled: January 8, 2015Date of Patent: September 10, 2019Assignee: GENMAB A/SInventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
-
Patent number: 10385133Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.Type: GrantFiled: September 9, 2016Date of Patent: August 20, 2019Assignee: E.R. Squibb & Sons, L.L.C.Inventors: Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
-
Patent number: 10377810Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.Type: GrantFiled: April 20, 2017Date of Patent: August 13, 2019Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTYInventor: Suzanne Ostrand-Rosenberg
-
Patent number: 10323099Abstract: Multispecific antibodies based on antibodies that share a common light chain are described herein. The multispecific antibodies include: modified heavy chains having, by domain exchange, a common light chain variable domain VL; and two modified light chains having, by domain exchange, variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of such antibodies and their use.Type: GrantFiled: April 7, 2016Date of Patent: June 18, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Peter Bruenker, Christiane Neumann, Christian Klein, Ekkehard Moessner, Wolfgang Schaefer
-
Patent number: 10287352Abstract: The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.Type: GrantFiled: September 29, 2016Date of Patent: May 14, 2019Assignee: HOFFMAN-LA ROCHE INC.Inventors: Laura Codarri-Deak, Georg Fertig, Jens Fischer, Christian Klein, Viktor Levitski, Valeria Lifke, Mario Perro, Joerg Thomas Regula, Tilman Schlothauer, Stefan Seeber, Pablo Umana, Ildiko Wuensche, Adrian Zwick
-
Patent number: 10266608Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.Type: GrantFiled: May 4, 2016Date of Patent: April 23, 2019Assignee: EpimAb Biotherapeutics, Inc.Inventor: Chengbin Wu